Polypill for the prevention of cardiovascular disease (PolyIran): Study design and rationale for a pragmatic cluster randomized controlled trial

European Journal of Preventive Cardiology

Volumn 22, Issue 12, 2015, Pages 1609-1617

  Ostovaneh, Mohammad Reza ^a,b   Poustchi, Hossein ^a   Hemming, Karla ^c   Marjani, Hajiamin ^d   Pourshams, Akram ^a   Nateghi, Alireza ^a   Majed, Masoud ^a   Navabakhsh, Behrouz ^a   Khoshnia, Masoud ^d   Jaafari, Elham ^a   Mohammadifard, Noushin ^e   Malekzadeh, Fatemeh ^a   Merat, Shahin ^a   Sadeghi, Masoumeh ^f   Naemi, Mohammad ^d   Etemadi, Arash ^a,g   Thomas, G Neil ^c   Sarrafzadegan, Nizal ^e   Cheng, K K ^c   Marshall, Tom ^c   Malekzadeh, Reza ^a   more..

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cardiovascular diseases; polypill; primary prevention; secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DRUG COST; DRUG EFFECT; DRUG SAFETY; FATALITY; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HEART FAILURE; HEART INFARCTION; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PILL; PRIMARY HEALTH CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SUDDEN DEATH; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG COMBINATION; IRAN; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; POLYPHARMACY; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; ATORVASTATIN CALCIUM; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOLS; DRUG COMBINATIONS; ENALAPRIL; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IRAN; MALE; MIDDLE AGED; POLYPHARMACY; PRIMARY PREVENTION; RESEARCH DESIGN; SECONDARY PREVENTION; SODIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VALSARTAN;

EID: 84940757679     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314550803     Document Type: Article

References (24)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013; 380: 2224-2260.
2. WHO. Non-communicable diseases (NCD). WHO 2012, http://www.who.int/gho/ncd/en/index.html (accessed 8 June 2014.
3. Law M, Wald N, Morris J,. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7: 1-94.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
5. Mendis S, Fukino K, Cameron A, et al. The availability and affordability of selected essential medicines for chronic diseases in six low-and middle-income countries. Bull World Health Organ 2007; 85: 279-288.
6. WHO. Adherence to long-term therapies-evidence for action. WHO 2003, http://www.who.int/chp/knowledge/publications/adherence-full-report.pdf (accessed 8 June 2014).
7. Wald NJ, Law MR,. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419-1419.
8. Sepanlou SG, Farzadfar F, Jafari E, et al. Cardiovascular disease prevention using fixed dose pharmaco-therapy in Iran: updated meta-snalyses and mortality estimation. Arch Iran Med 2012; 15: 531-537.
9. The Indian Polycap Study (TIPS), Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373: 1341-1351.
10. Rastegarpanah M, Malekzadeh F, Thomas GN, et al. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"? Arch Iran Med 2008; 11: 306-313.
11. Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract 2010; 64: 1220-1227.
12. Soliman EZ, Mendis S, Dissanayake WP, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials 2011; 12: 3-3.
13. Wald DS, Morris JK, Wald NJ,. Randomized polypill crossover trial in people aged 50 and over. PLoS One 2012; 7: e41297-e41297.
14. Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol 2014; 21: 252-261.
15. Pourshams A, Khademi H, Malekshah AF, et al. Cohort profile: the Golestan Cohort Study- A prospective study of oesophageal cancer in northern Iran. Int J Epidemiol 2010; 39: 52-59.
16. Farzadfar F, Murray CJ, Gakidou E, et al. Effectiveness of diabetes and hypertension management by rural primary health-care workers (Behvarz workers) in Iran: a nationally representative observational study. Lancet 2012; 379: 47-54.
17. Javanparast S, Baum F, Labonte R, et al. Community health workers' perspectives on their contribution to rural health and well-being in Iran. Am J Public Health 2011; 101: 2287-2292.
18. Khademi H, Malekzadeh R, Pourshams A, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ 2012; 344: e2502-e2502.
19. Carter BR, Hood K,. Balance algorithm for cluster randomized trials. BMC Med Res Methodol 2008; 8: 65-65.
20. Hemming K, Marsh J,. A menu-driven facility for sample-size calculations in cluster randomized controlled trials. The Stata Journal 2013; 13: 114-135.
21. Reddy KS,. The preventive polypill-much promise, insufficient evidence. N Engl J Med 2007; 356: 212-212.
22. Javanparast S, Baum F, Labonte R, et al. A policy review of the community health worker programme in Iran. J Public Health Policy 2011; 32: 263-276.
23. Rabiei K, Kelishadi R, Sarrafzadegan N, et al. Process evaluation of a community-based program for prevention and control of non-communicable disease in a developing country: The Isfahan Healthy Heart Program, Iran. BMC Public Health 2009; 9: 57-57.
24. Ware JH, Hamel MB,. Pragmatic trials-guides to better patient care. N Engl J Med 2011; 364: 1685-1687.